D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 133 SEK -3.62% Market Closed
Market Cap: 2.2B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-39.2
Current
-27.4
Median
4.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-39.2
=
Enterprise Value
2.1B SEK
/
EBITDA
-52.8m SEK
All Countries
Close
EBITDA Growth
SE
D
Devyser Diagnostics AB
STO:DVYSR
Average EV/EBITDA: 18
Negative Multiple: -39.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.8
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.9
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-48.7
2-Years Forward
EV/EBITDA
72.7
3-Years Forward
EV/EBITDA
21.9

See Also

Discover More